阿奇霉素联合头孢哌酮钠舒巴坦钠治疗小儿支原体肺炎的效果研究

Study on the effect of azithromycin combined with cefoperazone sodium and sulbactam sodium in the treatment of mycoplasma pneumonia in children

目的研究阿奇霉素联合头孢哌酮钠舒巴坦钠治疗小儿支原体肺炎的临床效果。方法70例小儿支原体肺炎患儿,随机分为对照组和观察组,各35例。对照组患儿单用阿奇霉素治疗,观察组患儿采用阿奇霉素联合头孢哌酮钠舒巴坦钠治疗。对比两组患儿临床疗效、临床症状消失时间、X线胸片恢复正常时间、用药安全性及治疗前后血清炎性因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]水平。结果观察组患儿治疗总有效率为97.14%(34/35),低于对照组的82.86%(29/35),差异具有统计学意义(P<0.05)。观察组患儿退热时间(3.67±1.33)d、咳嗽消失时间(3.37±0.54)d、肺部湿啰音消失时间(5.76±2.61)d及X线胸片恢复正常时间(8.26±2.22)d均短于对照组的(4.79±1.44)、(4.69±0.83)、(7.96±2.23)、(11.38±2.51)d,差异有统计学意义(P<0.05)。治疗后,观察组患儿hs-CRP(10.69±1.38)mg/L、TNF-α(19.05±5.57)ng/L均低于对照组的(19.68±2.14)mg/L、(24.70±6.10)ng/L,差异有统计学意义(P<0.05)。观察组患儿不良反应发生率为2.86%(1/35)低于对照组的17.14%(6/35),差异有统计学意义(P<0.05)。结论阿奇霉素联合头孢哌酮钠舒巴坦钠治疗小儿支原体肺炎有利于临床效果的提升,促进临床症状消失、X线胸片恢复,改善血清炎性因子水平,安全性高。

Objective To study the clinical effect of azithromycin combined with cefoperazone sodium and sulbactam sodium in the treatment of mycoplasma pneumonia in children.Methods A total of 70 children with mycoplasma pneumonia were randomly divided into control group and observation group,with 35 cases in each group.Children in the control group were treated with azithromycin alone,and children in the observation group were treated with azithromycin in combination with cefoperazone sodium and sulbactam sodium.Both groups were compared in terms of clinical efficacy,disappearance time of clinical symptoms,recovery time of chest X-ray,medication safety,and serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)]before and after treatment.Results The total effective rate of treatment in the observation group was 97.14%(34/35),which was lower than 82.86%(29/35)in the control group,and the difference was statistically significant(P<0.05).The duration of fever(3.67±1.33)d,cough disappearance time(3.37±0.54)d,lung wet rale disappearance time(5.76±2.61)d and recovery time of chest X-ray(8.26±2.22)d of the observation group were shorter than(4.79±1.44),(4.69±0.83),(7.96±2.23),and(11.38±2.51)d of the control group,and the difference was statistically significant(P<0.05).After treatment,the hs-CRP(10.69±1.38)mg/L and TNF-α(19.05±5.57)ng/L in the observation group were lower than(19.68±2.14)mg/L and(24.70±6.10)ng/L in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 2.86%(1/35)in the observation group was lower than 17.14%(6/35)in the control group,and the difference was statistically significant(P<0.05).Conclusion Azithromycin combined with cephalosporins in the treatment of mycoplasma pneumonia in children can improve the clinical effect,promote the disappearance of clinical symptoms,the recovery of chest X-ray,improve the level of serum inflammatory factors,and has high safety.